Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis.

Saleh RR, Antrás JF, Peinado P, Pérez-Segura P, Pandiella A, Amir E, Ocaña A.

Cancer Treat Rev. 2019 May 29;77:11-19. doi: 10.1016/j.ctrv.2019.05.006. [Epub ahead of print] Review.

PMID:
31174180
2.

The Voices of Young Women with Breast Cancer: Providing Support and Information for Improved Fertility Preservation Discussions.

Srikanthan A, Ethier JL, Amir E.

J Adolesc Young Adult Oncol. 2019 Jun 3. doi: 10.1089/jayao.2019.0030. [Epub ahead of print]

PMID:
31158039
3.

PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis.

Ghate K, Amir E, Kuksis M, Hernandez-Barajas D, Rodriguez-Romo L, Booth CM, Vera-Badillo FE.

Cancer Treat Rev. 2019 Jun;76:51-56. doi: 10.1016/j.ctrv.2019.05.002. Epub 2019 May 16. Review.

PMID:
31125908
4.

The Impact of Big Data Research on Practice, Policy, and Cancer Care.

Chambers DA, Amir E, Saleh RR, Rodin D, Keating NL, Osterman TJ, Chen JL.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e167-e175. doi: 10.1200/EDBK_238057. Epub 2019 May 17.

PMID:
31099675
5.

Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment.

Gyawali B, Hwang TJ, Vokinger KN, Booth CM, Amir E, Tibau A.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:374-387. doi: 10.1200/EDBK_242229. Epub 2019 May 17.

PMID:
31099613
6.

Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer-the 5C study: a study protocol for a randomised controlled phase III trial.

Puts MTE, Hsu T, Mariano C, Monette J, Brennenstuhl S, Pitters E, Ray J, Wan-Chow-Wah D, Kozlowski N, Krzyzanowska M, Amir E, Elser C, Jang R, Prica A, Krahn M, Beland F, Bergman S, Koneru R, Lemonde M, Szumacher E, Zidulka J, Fung S, Li A, Emmenegger U, Mehta R, Flemming K, Breunis H, Alibhai SMH.

BMJ Open. 2019 May 10;9(5):e024485. doi: 10.1136/bmjopen-2018-024485.

7.

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.

Morcillo-Garcia S, Noblejas-Lopez MDM, Nieto-Jimenez C, Perez-Peña J, Nuncia-Cantarero M, Győrffy B, Amir E, Pandiella A, Galan-Moya EM, Ocana A.

PLoS One. 2019 Apr 16;14(4):e0209134. doi: 10.1371/journal.pone.0209134. eCollection 2019.

8.

Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis.

Korzets Y, Fyles A, Shepshelovich D, Amir E, Goldvaser H.

Breast Cancer Res Treat. 2019 Jun;175(3):531-545. doi: 10.1007/s10549-019-05209-9. Epub 2019 Mar 30. Review.

PMID:
30929116
9.

Role of Bisphosphonates in Breast Cancer Therapy.

Goldvaser H, Amir E.

Curr Treat Options Oncol. 2019 Mar 14;20(4):26. doi: 10.1007/s11864-019-0623-8. Review.

PMID:
30874905
10.

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.

Jiang DM, Chan KKW, Jang RW, Booth C, Liu G, Amir E, Mason R, Everest L, Elimova E.

Cancer Med. 2019 Apr;8(4):1584-1593. doi: 10.1002/cam4.2058. Epub 2019 Mar 7.

11.

Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

Flaum N, Hubner RA, Valle JW, Amir E, McNamara MG.

J Surg Oncol. 2019 Jun;119(7):932-940. doi: 10.1002/jso.25440. Epub 2019 Mar 5.

PMID:
30838647
12.

Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.

Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S, Amir E, Thavendiranathan P.

Can J Cardiol. 2019 Feb;35(2):153-159. doi: 10.1016/j.cjca.2018.11.028. Epub 2018 Dec 4.

PMID:
30760421
13.

The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.

Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu JV, Fung K, Anderson GM.

J Natl Cancer Inst. 2019 Jan 31. doi: 10.1093/jnci/djy218. [Epub ahead of print]

PMID:
30715404
14.

Endpoint selection in HER2-positive early breast cancer.

Amir E.

Lancet Oncol. 2019 Mar;20(3):315-316. doi: 10.1016/S1470-2045(18)30779-4. Epub 2019 Jan 29. No abstract available.

PMID:
30709632
15.

Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.

Shepshelovich D, Tibau A, Goldvaser H, Ocana A, Seruga B, Amir E.

Mayo Clin Proc. 2019 Jan;94(1):74-83. doi: 10.1016/j.mayocp.2018.07.027.

PMID:
30611457
16.

Pilot Study of a Transitional Intervention for Family Caregivers of Older Adults.

McCusker J, Lambert SD, Yaffe MJ, Cole MG, Hidalgo M, Amir E, de Raad M, Belzile E.

Can J Aging. 2018 Dec 27:1-12. doi: 10.1017/S071498081800051X. [Epub ahead of print]

PMID:
30587251
17.

Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual.

Shepshelovich D, Tibau A, Molto C, Goldvaser H, Ocana A, Šeruga B, Amir E.

JAMA Oncol. 2019 Jan 1;5(1):107-109. doi: 10.1001/jamaoncol.2018.5877. No abstract available.

PMID:
30520936
18.

An integrated framework using high-dimensional mass cytometry and fluorescent flow cytometry identifies discrete B cell subsets in patients with red meat allergy.

Cox KM, Commins SP, Capaldo BJ, Workman LJ, Platts-Mills TAE, Amir ED, Lannigan JA, Schuyler AJ, Erickson LD.

Clin Exp Allergy. 2019 May;49(5):615-625. doi: 10.1111/cea.13322. Epub 2019 Jan 8.

PMID:
30506749
19.

A prospective intervention to improve happiness and reduce burnout in oncologists.

Clemons M, Mazzarello S, Pond G, Amir E, Asmis T, Berry S, Brackstone M, Brule S, Goodwin R, Hilton JF, Julião M, Nicholas G, Stewart DJ, Wheatley-Price P, Cholmsky L, Krentel A, Hutton B, Joy AA.

Support Care Cancer. 2019 Apr;27(4):1563-1572. doi: 10.1007/s00520-018-4567-5. Epub 2018 Nov 30.

PMID:
30506102
20.

Competing risks of extended adjuvant aromatase inhibitors.

Amir E.

Lancet Oncol. 2019 Jan;20(1):8-9. doi: 10.1016/S1470-2045(18)30663-6. Epub 2018 Nov 30. No abstract available.

PMID:
30509770
21.

Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.

Kitchlu A, McArthur E, Amir E, Booth CM, Sutradhar R, Majeed H, Nash DM, Silver SA, Garg AX, Chan CT, Kim SJ, Wald R.

J Natl Cancer Inst. 2018 Nov 13. doi: 10.1093/jnci/djy167. [Epub ahead of print]

PMID:
30423160
22.

Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.

McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E.

Eur J Cancer. 2018 Dec;105:1-9. doi: 10.1016/j.ejca.2018.09.031. Epub 2018 Oct 29.

PMID:
30384012
23.

Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis.

Goldvaser H, Ribnikar D, Majeed H, Ocaña A, Amir E.

Cancer Treat Rev. 2018 Dec;71:68-75. doi: 10.1016/j.ctrv.2018.10.010. Epub 2018 Oct 17. Review.

PMID:
30366201
24.

Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens.

Wroblewska A, Dhainaut M, Ben-Zvi B, Rose SA, Park ES, Amir ED, Bektesevic A, Baccarini A, Merad M, Rahman AH, Brown BD.

Cell. 2018 Nov 1;175(4):1141-1155.e16. doi: 10.1016/j.cell.2018.09.022. Epub 2018 Oct 18.

PMID:
30343902
25.

Cardiac Outcomes in Pregnant Women With Treated Cancer.

Liu S, Aghel N, Belford L, Silversides CK, Nolan M, Amir E, Maxwell C, Thavendiranathan P.

J Am Coll Cardiol. 2018 Oct 23;72(17):2087-2089. doi: 10.1016/j.jacc.2018.07.085. No abstract available.

PMID:
30336834
26.

Refining Early Antitumoral Drug Development.

Ocaña A, García-Alonso S, Amir E, Pandiella A.

Trends Pharmacol Sci. 2018 Nov;39(11):922-925. doi: 10.1016/j.tips.2018.09.003. Epub 2018 Sep 29. Review.

PMID:
30279003
27.

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials.

Tibau A, Molto C, Borrell M, Del Paggio JC, Barnadas A, Booth CM, Amir E.

JAMA Oncol. 2018 Nov 1;4(11):1610-1611. doi: 10.1001/jamaoncol.2018.4300. No abstract available.

PMID:
30267037
28.

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.

Pérez-Peña J, Győrffy B, Amir E, Pandiella A, Ocaña A.

Breast Cancer Res Treat. 2018 Dec;172(3):725-732. doi: 10.1007/s10549-018-4965-x. Epub 2018 Sep 11.

PMID:
30206781
29.

Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy.

Algorashi I, Goldvaser H, Ribnikar D, Cescon DW, Amir E.

Cancer Treat Rev. 2018 Nov;70:138-143. doi: 10.1016/j.ctrv.2018.08.009. Epub 2018 Aug 24. Review.

PMID:
30176513
30.

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results.

Ocaña A, Amir E, Pandiella A.

Oncotarget. 2018 Aug 7;9(61):31915-31919. doi: 10.18632/oncotarget.25739. eCollection 2018 Aug 7. Review.

31.

Comprehensive innate immune profiling of chikungunya virus infection in pediatric cases.

Michlmayr D, Pak TR, Rahman AH, Amir ED, Kim EY, Kim-Schulze S, Suprun M, Stewart MG, Thomas GP, Balmaseda A, Wang L, Zhu J, Suaréz-Fariñas M, Wolinsky SM, Kasarskis A, Harris E.

Mol Syst Biol. 2018 Aug 27;14(8):e7862. doi: 10.15252/msb.20177862.

32.

Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?

Shepshelovich D, Amir E.

Oncotarget. 2018 Jul 24;9(57):30942-30943. doi: 10.18632/oncotarget.25799. eCollection 2018 Jul 24. No abstract available.

33.

Unmet needs of family caregivers of hospitalized older adults preparing for discharge home.

McCusker J, Yaffe M, Lambert SD, Cole M, de Raad M, Belzile E, Ciampi A, Amir E, Hidalgo M.

Chronic Illn. 2018 Aug 4:1742395318789467. doi: 10.1177/1742395318789467. [Epub ahead of print]

PMID:
30079741
34.

Health status, emergency department visits, and oncologists' feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trial.

Sattar S, Alibhai SMH, Brennenstuhl S, Kulik M, MacDonald ME, McWatters K, Lee K, Jang R, Amir E, Krzyzanowska MK, Joshua AM, Monette J, Wan-Chow-Wah D, Puts MTE.

J Geriatr Oncol. 2019 Jan;10(1):169-174. doi: 10.1016/j.jgo.2018.06.014. Epub 2018 Jul 21.

PMID:
30041978
35.

Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer.

Lohmann AE, Dowling RJO, Ennis M, Amir E, Elser C, Brezden-Masley C, Vandenberg T, Lee E, Fazaee K, Stambolic V, Goodwin PJ, Chang MC.

JNCI Cancer Spectr. 2018 Apr;2(2):pky028. doi: 10.1093/jncics/pky028. Epub 2018 Jul 12.

36.

Catalytic Functionalization of C-H Bonds of Azulene by Carbene/Nitrene Incorporation.

Carreras J, Popowski Y, Caballero A, Amir E, Pérez PJ.

J Org Chem. 2018 Sep 21;83(18):11125-11132. doi: 10.1021/acs.joc.8b01731. Epub 2018 Jul 26.

PMID:
30032616
37.

Importance of Considering Competing Risks in Time-to-Event Analyses: Application to Stroke Risk in a Retrospective Cohort Study of Elderly Patients With Atrial Fibrillation.

Abdel-Qadir H, Fang J, Lee DS, Tu JV, Amir E, Austin PC, Anderson GM.

Circ Cardiovasc Qual Outcomes. 2018 Jul;11(7):e004580. doi: 10.1161/CIRCOUTCOMES.118.004580.

PMID:
29997149
38.

Representation of Patients With Chronic Kidney Disease in Trials of Cancer Therapy.

Kitchlu A, Shapiro J, Amir E, Garg AX, Kim SJ, Wald R, Harel Z.

JAMA. 2018 Jun 19;319(23):2437-2439. doi: 10.1001/jama.2018.7260. No abstract available.

PMID:
29922818
39.

Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer.

Majeed H, Amir E.

J Thorac Dis. 2018 Apr;10(Suppl 9):S995-S998. doi: 10.21037/jtd.2018.03.153. No abstract available.

40.

Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis.

Salah S, Lewin J, Amir E, Abdul Razak A.

Cancer Treat Rev. 2018 Sep;69:1-10. doi: 10.1016/j.ctrv.2018.05.007. Epub 2018 May 19. Review.

PMID:
29843049
41.

Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study.

Thavendiranathan P, Abdel-Qadir H, Fischer HD, Liu Y, Camacho X, Amir E, Austin PC, Lee DS.

J Clin Oncol. 2018 Oct 20;36(30):2980-2987. doi: 10.1200/JCO.2018.77.9736. Epub 2018 May 23.

PMID:
29791284
42.

Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy.

Templeton AJ, Rodríguez-Lescure Á, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia-Marco JM, Lluch A, Álvarez I, Casas MI, Sánchez-Aragó M, Caballero R, Carrasco E, Amir E, Martin M, Ocaña A; GEICAM 9906 Study Investigators.

Clin Transl Oncol. 2018 Dec;20(12):1548-1556. doi: 10.1007/s12094-018-1885-5. Epub 2018 May 15.

PMID:
29766456
43.

A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.

Dhillon P, Amir E, Lo M, Kitchlu A, Chan C, Cochlin S, Yip P, Chen E, Lee R, Ng P.

J Oncol Pharm Pract. 2019 Jun;25(4):875-883. doi: 10.1177/1078155218771461. Epub 2018 May 3.

PMID:
29722605
44.

Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.

Shepshelovich D, Tibau A, Goldvaser H, Molto C, Ocana A, Seruga B, Amir E.

J Clin Oncol. 2018 Jun 20;36(18):1798-1804. doi: 10.1200/JCO.2017.77.5593. Epub 2018 Apr 11.

PMID:
29641296
45.

Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer.

Tibau A, Anguera G, Andrés-Pretel F, Templeton AJ, Seruga B, Barnadas A, Amir E, Ocana A.

Oncotarget. 2018 Feb 28;9(19):15061-15067. doi: 10.18632/oncotarget.24589. eCollection 2018 Mar 13.

46.

Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.

Martínez-Canales S, López de Rodas M, Nuncia-Cantarero M, Páez R, Amir E, Győrffy B, Pandiella A, Galán-Moya EM, Ocaña A.

Cancer Med. 2018 May;7(5):1896-1907. doi: 10.1002/cam4.1406. Epub 2018 Mar 25.

47.

Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.

Ethier JL, Ocaña A, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia Marco J, Lluch A, Álvarez I, Casas M, Sánchez-Aragó M, Carrasco E, Caballero R, Amir E, Martin M.

Eur J Cancer. 2018 May;94:199-205. doi: 10.1016/j.ejca.2018.02.018. Epub 2018 Mar 21.

PMID:
29573665
48.

Response.

Tibau A, Molto C, Amir E.

J Natl Cancer Inst. 2018 Oct 1;110(10):1145. doi: 10.1093/jnci/djy031. No abstract available.

PMID:
29529214
49.

EQUATOR-Oncology: reducing the latitude of cancer trial design and reporting.

Majeed H, Amir E.

Br J Cancer. 2018 Mar 6;118(5):617-618. doi: 10.1038/bjc.2017.427. Epub 2018 Feb 22. No abstract available.

50.

Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.

Goldvaser H, Majeed H, Ribnikar D, Šeruga B, Ocaña A, Cescon DW, Amir E.

Breast Cancer Res Treat. 2018 Jun;169(3):413-425. doi: 10.1007/s10549-018-4710-5. Epub 2018 Feb 8. Review.

PMID:
29423899

Supplemental Content

Support Center